drugset

drugset / Trial / NCT03494270

High-intensity Rosuvastatin and Moderate-intensity Rosuvastatin/Ezetimibe in ASCVD Patients

NCT03494270 ↗

Phase 4 Completed 270 enrolled Yuhan Corporation

RandomizedParallel-groupOpen-labelTreatment

Summary

This study will evaluate the efficacy and safety of high-intensity rosuvastatin and moderate-intensity rosuvastatin/ezetimibe in ASCVD patients.

Timeline

Start: 2018-03-18
Primary completion: 2019-09-26
Completion: 2019-09-26

Publications

Choi H, Kang SH, Jeong SW, Yoon CH, Youn TJ, Song WH, Jeon DW, Lim SW, Lee JH, Cho SW, Chae IH, Kim CH. Lipid-Lowering Efficacy of Combination Therapy With Moderate-Intensity Statin and Ezetimibe Versus High-Intensity Statin Monotherapy: A Randomized, Open-Label, Non-Inferiority Trial From Korea. J Lipid Atheroscler. 2023 Sep;12(3):277-289. doi: 10.12997/jla.2023.12.3.277. Epub 2023 Aug 3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ezetimibe	Unknown	10 mg	—
Subject	Rosuvastatin	Small molecule	10 mg	—
Subject	Rosuvastatin	Small molecule	20 mg	—

Indications